Ablivas CEO to BioStock: “We remain on track for the interim analysis early in Q3”
During the first quarter of 2024, Abliva focused on progressing the FALCON clinical trial towards interim analysis, securing necessary financing, and increasing the company’s visibility within the mitochondrial disease community. With funding secured, the team has all the chess pieces in place for a mid-year readout.
– In their analysis, the DMC will review the safety profile of KL1333 and the potential of the study to achieve statistical significance after the full 48 weeks of dosing, says Abliva’s CEO Ellen Donnelly.
Read the full interview with Ellen Donnelly at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/